Drug screening is the process by which potential drugs are identified and optimized prior selection of a candidate drug to process to clinical trials. This involves screening of wide range of drug libraries of chemicals for a particular biological activity in throughput screening assays.
Rising prevalence of infectious diseases, stringent regulations proposed by the government regarding drugs act, rigorous R&D activities, and companies launching new product to stay forefront in the global market drives the drug screening market globally.
Center for Drug Evaluation and Research (CDER) develops Food and Drug Administration (FDA) policy in response to safety, effectiveness, and labeling of drugs for human use. This process supports evaluation of new drug application and investigational approach towards new drug development process. Moreover, drug regulatory research conducted by CDER have positive influence on the public health by ensuring that marketed drugs are safe and efficacious and their risk associated profile and benefit profile remains acceptable during the market life of a drug.
Key Takeaways: Drug Screening Market
FDA’s regulatory decisions start with preliminary focus upon discovery and development of new drugs. Typically, researchers discover new drugs through insights for a disease that provoke to design a product that stop or reverse the effects of disease. Many tests related to molecular compounds and new technologies are developed that provide new ways to target medical products to specific sites within the body to manipulate to generate genetic material. Furthermore, in the development stage, researchers identify a promising compound for the development that involves experiments. Experiments are conducted to study pharmacology/toxicology, microbiology/virology, clinical pharmacology, pediatric issues. Moreover, the experiments help to detect pharmacological actions for different groups of people by gender, race or ethnicity, and its route of administration.
Trending: Novel Drug Delivery System
Evolution of existing drug molecule from its traditional form to a novel drug delivery system can significantly improve its performance related to patient compliance, safety, and efficacy. The newly designed novel drug delivery system acts as a major factor for solving problems associated with the release of drug at specific sites with specific rate after administration. The need for delivering drugs to patients efficiently coupled with fewer side effects has gained strong attention by the pharmaceutical companies that engage in the development of new drug delivery system.
On the other hand, controlling the pharmacokinetics, pharmacodynamics, immunogenicity, non-specific toxicity, biorecognition, and efficacy of drugs were generated. These new strategies are often called drug delivery system (DDS). To minimize drug degradation and loss, adverse effects, increasing bioavailability, and drug accumulation raise the demand for drug delivery system (DDS) and drug targeting systems that are currently under development stage. Currently, controlled and novel drug delivery is a reality. Several pharmaceutical companies carry extensive research and investigations in the field of drug research.
In 2017, Indian Institute of Science Education and Research (IISER), announced successful development of novel cancer drug delivery system using graphene oxide nanoparticles. Further, it was found that graphene oxide is a cheaply abundant carbon-based material that can be used for several applications ranging from material science to biomedical research.
Rigorous research and development (R&D) activities is the prominent factor that bolster the overall growth of drug screening market globally. In addition, incorporating different drugs in the product and launching in the market by prominent players spur the growth of drug screening market worldwide. New product formulation by incorporating appropriate drug for preventing novel spread of any disease that occurs in humans more often. New drug discovery by the researchers for novel drug delivery system for humans suffering from severe diseases like cancer.
Big Calls for “Research and Development (R&D) Activities”
Rising innovative pharmaceutical drug discovery has grabbed a significant attention in the global market for drug screening. The most expensive aspect of R&D is clinical trials. This is accounted for 60% of the R&D costs. In 2017, pharmaceutical companies spent annually US$ 71 Bn in R&D and actual cost to bring a drug to the market was US$ 1.8 Bn. Drug development and R&D are gaining a strong pace in the worldwide market. Several researchers and scientists are having strong control over adoption of wide range of microscopes and more IT specialist’s tool for getting fast results.
The key Players launching new products in the market through integration of new drug entities uplift the overall market of drug screening globally. In January 2020, Sumitomo Dainippon Pharma in collaboration with Exscientia announced that drug DSP-1181 that was in Phase 1 clinical study created using Artificial Intelligence (AI) has received approval in Japan. The new drug will plays a vital role for the treatment of obsessive compulsive disorder (OCD) as a clinical indication.
Drug screening market is based on disease, delivery system, and end-user. By disease, the market is segmented as cancer, obsessive compulsive disorder (OCD), acute hepatic porphyria, postpartum depression, tenosynovial giant cell tumor, and others. Delivery system, the product is segmented into novel drug delivery system (NDDS), sustained release drugs, drug delivery system (DDS), and systemic drugs release, disease targeting drugs. Finally, end-user segment is categorized as drug testing laboratories, drug treatment centers, clinical labs, research laboratories, and others.
Based on delivery system, novel drug delivery system (NDDS) will gain a significant pace in the coming years. This is attributed to rising need for control release of drugs, advancements in pharmacological studies, and technological advancements promoting development of NDDS.
Currently, nanomedicine and nano delivery system has gained a prominent attention in the global market. Rapidly changing science coupled with R&D activities has witnessed a drastic shift in drug delivery studies. Materials in the nano scale range serves as a diagnostic tool or deliver therapeutic agents to specific target sites in controlled form has increased widely in the minds of the key players. Nanotechnology provides multiple benefits in treating chronic human disease by site-specific and target oriented delivery of precise medicines. Nano-drug delivery system (NDDS)are a class of nanomaterials that have the abilities to increase stability and water solubility of drugs, prolong the life cycle time, increase the uptake rate of target cells or tissues, reduce enzyme degradation, and improve safety and efficacy of drugs.
The critical component of nanotechnology research is to encourage the use of advanced manufacturing technique to produce liposomes and other nanomaterials in a way that reduces variation in product quality. From last five years, Office of Testing and Research (OTR) have been collaborating with scientists of University of Connecticut to develop a platform for continuous manufacturing of nanomaterials that should possess better control over the manufacturing and quality control process and lead to higher quality products.
North America will record significant market share for drug screening market in the coming years followed by Europe. The factors involve presence of largest drug testing laboratories, wide range of collection sites, and qualified team of researchers and healthcare professionals.
The US Drug Test Centers is one of the largest drug testing companies in the United States. The center is equipped with high capacity collection site of over 20,000 that provide drug and alcohol testing nationwide. Also, US Drug Test Centers is highly specialized in federal DOT drug testing, non-DOT drug testing, alcohol testing, random consortiums, and drug-free workplace programs.
On the other hand, Europe is an important market for drugs supplied from both domestic production and trafficking from other world regions. Europe is also a high producer of cannabis and synthetic drugs that involve cannabis production majorly in European nations whereas synthetic drugs are manufactured for the European markets and exported to other parts of the world. Drugs used in Europe comprises a wide range of substances. Among the population, polydrug consumption is common but challenging to measure from experimental, habitual, and dependant consumption.
Key companies profiled in this report involve LabCorp Quest Diagnostics, Alere, OraSure, Alfa Scientific Designs, Thermo Fisher Scientific, Drägerwerk, LifeLoc, MPD Inc., Omega Laboratories, Premier Biotech, Psychemedics, Roche, Shimadzu, Siemens Healthineers, American Bio Medica Corporation, Sciteck, Inc., ACM Global Laboratories, CareHealth America, and Clinical Reference Laboratory.
Market By Disease
Obsessive Compulsive Disorder (OCD)
Acute Hepatic Porphyria
Tenosynovial Giant Cell Tumor
Market By Delivery system
Novel Drug Delivery System (NDDS)
Sustained Release Drugs
Drug Delivery System (DDS)
Systemic Drugs Release
Disease Targeting Drugs
Market By End-User
Drug Testing Laboratories
Drug Treatment Centers
Market By Geography
Middle East & Africa